NVS NOVARTIS AG — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$157.53

Period return

+8.85 (+5.95%)

Volume

1.5M

2026-07-30O $156.91 H $157.78 L $156.46 C $157.53MA5 $157.47MA20 $154.86MA60 $151.61MA120 $153.34

6M · 125 barsYahoo Finance · USD2026-01-30 → 2026-07-30

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.High3 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.08%
2026. 05. 15.High3 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	283,837	$43.36M	0.08%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	27,528	$4.2M	0.00%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	29,928	$4.13M	0.01%	—	New position

NOVARTIS AG

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats